新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 癌症研究 » JAMA Dermatol:常规心脏病药物或可帮助治疗致死性癌症血管肉瘤

JAMA Dermatol:常规心脏病药物或可帮助治疗致死性癌症血管肉瘤

来源:生物谷 2015-11-09 11:16

图片来源:medicalxpress.com

2015年11月9日 讯 /生物谷BIOON/ --近日,一项刊登在国际杂志JAMA Dermatology上的研究论文中,来自美国德州理工大学健康科学中心的科学家通过研究发现,一种常见的心脏病药物或可阻断癌症血管肉瘤的进展,血管肉瘤是癌症组织中血管的内层组织,其作为一种高度致命性的肿瘤可以在机体任何部位发生,肿瘤典型地可以以皮肤生长或损伤的方式来出现,其生长的越大,对个体致死的风险就越大。

早在2014年,研究者就对一名左脸颊、额头和头皮上都有扩大癌症病变损伤的患者进行研究,活组织检查结果显示,这是一种血管肉瘤,而该名患者结果并不良好;研究者在当时的文章中就写道,基于当前的标准化疗法我们并没有合适的方法来对这种全身呈现快速扩张均一致死性肿瘤的患者进行治疗。

本文研究中,研究者发现,一种可以用于治疗高血压的药物普萘洛尔或许可以有效抵御血管肉瘤,随后研究者就开始利用这种药物进行大量的实验,进行一周的普萘洛尔治疗后,肿瘤停止了其快速生长,并且没有表现出任何临床扩张和延伸的迹象;使用普萘洛尔6个月后,伴随化疗和放疗的联合治疗,病人机体的肿瘤检测不到了。

本文研究显示,药物普萘洛尔或许可以潜在帮助抵御血管肉瘤,当前治疗肉瘤的处方药物对于患者而言每个月话费超过1万美元,而药物普萘洛尔仅为每个月4美元;最后研究者Bryan指出,如果该药物的使用可以扩大到更多患者,那么普萘洛尔的管理或许对于大规模治疗血管肉瘤的患者将是一大改进,当前我们正在进行II期临床试验来检测普萘洛尔的有效性来降低乳腺癌患者机体肿瘤的生长,如果研究结果非常积极有效,那么该试验将会扩大到对多种常见肿瘤进行研究。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷APP.

Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade

William Chow, DO1; Clarissa N. Amaya, MS2; Steven Rains, MS2; Michael Chow, BS1; Erin B. Dickerson, PhD3,4; Brad A. Bryan, PhD, MBA2

Importance Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than 10 cm demonstrate a 2-year survival rate of 0%. To our knowledge, major therapeutic advances against this disease have not been reported for decades. Preclinical data indicate that blocking β-adrenergic signaling with propranolol hydrochloride disrupts angiosarcoma cell survival and xenograft angiosarcoma progression. Observations A patient presented with a β-adrenergic–positive multifocal stage T2 cutaneous angiosarcoma (≥20 cm) involving 80% of the scalp, left forehead, and left cheek, with no evidence of metastasis. The patient was immediately administered propranolol hydrochloride, 40 mg twice a day, as his workup progressed and treatment options were elucidated. Evaluation of the proliferative index of the tumor before and after only 1 week of propranolol monotherapy revealed a reduction in the proliferative index of the tumor by approximately 34%. A combination of propranolol hydrochloride, 40 mg 3 times a day, paclitaxel poliglumex, 2 mg/m2 infused weekly, and radiotherapy during the subsequent 8 months resulted in extensive tumor regression with no detectable metastases. Conclusions and Relevance Our data suggest that β-blockade alone substantially reduced angiosarcoma proliferation and, in combination with standard therapy, is effective for reducing the size of the tumor and preventing metastases. If successful, β-blockade could be the first major advancement in the treatment of angiosarcoma in decades.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库